Valeant ups the ante in faceoff with Paladin to acquire Afexa

At least on analyst says Paladin could go as high as $1 per share as it attempts a hostile takeover of Afexa, as Valeant sweetens the pot with its friendly takeover offer

Register for free to listen to this article
Listen with Speechify
0:00
5:00
MISSISSAUGA, Ontario—Mere hours after Paladin Labs Inc. confirmedSept. 26 that it is increasing its offer to acquire any and all of the issuedand outstanding common shares of Afexa Life Sciences Inc. to 81 cents per share,Valeant Pharmaceuticals International Inc. said it will increase its own offerto 85 cents per share, which is a 20 percent premium on its previousoffer of 71 cents per share made in August—a total value of about $78million.
 
 
Valeant is in a bidding war with Montreal-based Paladin Labs,which launched a hostile takeover bid for Afexa in August, as we reported in anAug. 30 daily news story on the ddnwebsite. Paladin already owns about 15 percent of Afexa's stock, but Afexa's board of directors has been favoring the idea of a friendly takeover by Valeant.

"We have decided to offer a premium to Paladin Labs' mostrecent proposal as we are able to attribute more value than Paladin to theAfexa business given both our larger scale and resources in Canada, coupledwith our extensive international consumer footprint," said J. Michael Pearson,chairman and CEO of Valeant, in announcing the offer increase. "While wenormally don't participate in an auction process, given that our existing offerhas the full support of the board and management of Afexa, we felt it wasappropriate to continue to respond quickly to Paladin's hostile overtures."
 
 
Although Afexa hadn't made any official statement as of Sept. 28 (when this story was posted) regardingthe latest twist in this battle to acquire it, Afexa's chairman, William White,had noted in a Sept. 22 news release, when Paladin had announced an intent toincrease its hostile offer, "We are pleased that Paladin has finallyacknowledged that the value of Afexa significantly exceeds the $0.55 per shareoffer they originally made. Although we welcome a higher bid from Paladin, wewill oppose their application tomorrow before the Alberta Securities Commissionto cease-trade our shareholder rights plans because we believe that these planscontinue to have value by allowing Afexa to seek and consider competing bidsand by preventing Paladin from attaining a blocking position through marketpurchases or by taking up any and all shares tendered to its bid which coulddeter or frustrate other bids. Should Paladin choose to increase their offer,we would invite them to further amend their offer at the same time to include aminimum tender condition so that they will only acquire control of Afexa if amajority of our shareholders (other than Paladin) support their bid."
 
 
As it happens, the Alberta Securities Commission did strikedown Afexa's "poison pills" (the shareholder rights plans) that had stood inthe way of Paladin's bid, keeping Paladin in the fight to win Afexa.
 
 
The brass ring that both Valeant and Paladin are after is over-the-counterflu remedy Cold-FX, sales for which Valeant plans to boost by marketing it inthe United States and globally—such as in Australia, Latin America andCentral Europe—if it successfully acquires Edmonton-based Afexa. Valeantalready sells several over-the-counter products in countries such as the U.S.,Mexico and Australia, including moisturizers, skin care products and acnetreatments.
 
 
"Cold-FX is obviously the driver," Pearson said in aninterview with The Canadian Press. "Whatwe believe we can do is take this product, which is already well established inCanada, and establish it in other markets which will expand that growth."
 
 
Mark Beaudet, interim chief executive of Paladin,maintains that his company's offer is superior to Valeant's because Afexashareholders can get access to Paladin shares. "The share alternative givesAfexa shareholders the choice of continuing to have an interest in Cold-FX andin the specialty pharmaceutical sector by accepting shares in Paladin," hesaid. "The Valeant bid provides neither the value nor the choice of Paladin's enhancedoffer."
 
 
"Valeant's quick and decisive response to Paladin's latestbid suggests to us that it is also highly interested in the Afexa assets, andthat it could seek to outbid a potential increased offer from Paladin," noted Desjardinsanalyst Pooya Hemami in a research note, adding that Paladin would record agross trading profit of several million dollars if Valeant's increased bid isultimately successful. On the other hand, he noted, Paladin could continue toup the ante itself, and he predicted the company might ultimately go as high asbetween 90 cents and $1 per share.



Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue